U.S. President Donald Trump listens to remarks during a swearing-in ceremony for Administrator of the Centers for Medicare and Medicaid Services Mehmet Oz in the Oval Office in Washington, D.C., U.S., April 18, 2025. REUTERS/Nathan Howard/File Photo

Proposed experiment would allow states and Medicare drug plans to cover GLP-1 drugs like Ozempic and Wegovy for obesity, The Washington Post reports.

Obesity drugmakers Eli Lilly (NYSE:LLY) and Novo Nordisk (NVO) traded higher in the premarket on Friday after The Washington Post reported that the Trump Administration plans to cover weight loss drugs for some Medicare and Medicaid enrollees under a five-year experimental program.